Ask AI
Translating Discoveries in cSCC

CE / CME

Clinical Focus: Translating Discoveries Into Clinical Practice to Advance the Care of Patients With Cutaneous Squamous Cell Carcinoma

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: January 26, 2026

Expiration: July 25, 2026

Activity

Progress
1 2
Course Completed

For those who practice in academic or community settings, please indicate your practice setting

How many people with skin cancer do you provide care for in a typical month?

Which of the following best describes your specialty?

You are counseling a patient with resectable, high-risk cutaneous squamous cell carcinoma (cSCC) following a complete surgical excision. Which of the following immune checkpoint inhibitors (ICIs) would you discuss as an FDA-approved adjuvant therapy proven to significantly reduce the risk of disease recurrence?

Which of the following patients with cutaneous squamous cell carcinoma (cSCC) would be the best candidate for enrollment in a clinical trial of intralesional PD-1 immunotherapy?

In your practice, what level of PD-L1 expression would you consider appropriate to identify patients with high-risk cSCC, based on clinical features such as deep invasion or perineural involvement, as candidates for treatment with a PD-1 inhibitor?

A 72-year-old man with resected, very high–risk cutaneous squamous cell carcinoma (cSCC) is receiving adjuvant cemiplimab. After 3 months of therapy, he develops grade 3 immune-mediated colitis. Infectious workup is negative

What is the most appropriate management?